title: Pharmacokinetics of atenolol and its clinical consequences in patients with angina pectoris.
abstract: Pharmacokinetics and clinical effects of daily oral doses of 100 mg and 200 mg atenolol, respectively, were studied in patients with angina pectoris by means of a double-blind cross-over randomized study. Half-lives and areas under the curve were of the same magnitude as described earlier for healthy volunteers and hypertensive patients. However, a steady state level was built up during 4-week medication of 100 mg or 200 mg atenolol daily. Intra-patient correlations of plasma levels and reductions in exercising heart rate were moderate (r = 0.56-0.85). Only plasma levels and exercising heart rates revealed significant differences after a 100 mg and 200 mg dose. These findings, together with the remaining clinical observations, demonstrated that a single daily dose of 100 mg atenolol is useful in patients with exercise-induced angina pectoris.
mesh_terms: D000787:Angina Pectoris / Q000188:drug therapy*; D001262:Atenolol / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000378:metabolism*
chemical_list: D011412:Propanolamines; D001262:Atenolol